Back to search results

POSTPOD Trial: Continuous Glucose Monitoring for Type 2 Diabetes Risk After Gestational Diabetes

This study, called the POSTPOD Trial, is looking at how well a continuous glucose monitor (CGM) can predict your risk of developing Type 2 Diabetes after you've had gestational diabetes. You would wear a CGM sensor for 24 hours immediately after delivery. Researchers will compare the information from the CGM to standard tests like the 2-hour glucose tolerance test and HbA1c to see if the CGM is a good way to assess your long-term risk. This is a pilot study, meaning it's a small-scale test, and aims to enroll 50 women. To join, you must be at least 18 years old, receive prenatal care at UCLA Health, plan to deliver at UCLA Ronald Reagan or Santa Monica, and have a confirmed diagnosis of gestational diabetes.

Study design
This is an interventional pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) in 50 participants.
What's involved
You would wear a continuous glucose monitor for 24 hours immediately after delivery. You would also complete two surveys at 1-3 months postpartum and 12-14 months postpartum.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12-14 months postpartum, with surveys at 1-3 months and 12-14 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07449039

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

Recruiting
NAAges 18+Interventional
University of California, Los Angeles
~50 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:Continuous Glucose Monistor

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test
Measured over 24 hours postpartum and 1-3 months postpartum
+1 more outcome measured

Conditions

Gestational Diabetes Mellitus in Pregnancy

Explore related trials

Gestational Diabetes

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Christina Han, MD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

Rujuta Sathe
[email protected]
310-794-8893
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Prenatal care at UCLA Health
Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
Confirmed gestational diabetes diagnosis based on 2-step approach
Maternal age \>= 18 years

Exclusion

Pre-gestational diabetes (T1DM or T2DM)
Multifetal gestation
Intra-amniotic infection by clinical criteria
Postpartum hemorrhage
Maternal ICU admission
Known allergy to medical-grade adhesive
Presence of skin lesions at anticipated CGM application site
Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
Metformin use
Steroid use
Terbutaline use within 4 hours of delivery
Cystic fibrosis
MODY (mature onset of diabetes in the young)

What this trial measures

  • Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test24 hours postpartum and 1-3 months postpartum

    Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT

  • Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum24 hours postpartum and 1-3 months postpartum

    Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c